title: Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium.
authors.affiliation: Howard Hughes Medical Institute, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242.
authors.forename: M J
authors.initials: MJ
authors.lastname: Welsh
authors.forename: A E
authors.initials: AE
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Zabner
authors.forename: D P
authors.initials: DP
authors.lastname: Rich
authors.forename: S M
authors.initials: SM
authors.lastname: Graham
authors.forename: R J
authors.initials: RJ
authors.lastname: Gregory
authors.forename: B M
authors.initials: BM
authors.lastname: Pratt
authors.forename: R A
authors.initials: RA
authors.lastname: Moscicki
mesh_terms: D000260:Adenoviruses, Human / Q000502:physiology; D000281:Administration, Intranasal; D002985:Clinical Protocols; D003264:Containment of Biohazards; D003550:Cystic Fibrosis / Q000235:genetics / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D003673:Defective Viruses / Q000502:physiology; D004848:Epithelium; D005069:Evaluation Studies as Topic; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D009297:Nasal Mucosa; D012306:Risk; D012449:Safety; D014779:Virus Replication
chemical_list: C505032:CFTR protein, human; D008565:Membrane Proteins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator